Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilie Dugast

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Journal of Autoimmunity|October 22, 2017
An intermediate level of CD161 expression defines a novel activated, inflammatory, and pathogenic subset of CD8<sup>+</sup> T cells involved in multiple sclerosisBryan Nicol, Marion Salou, Isabel Vogel, et al.
Brain Communications|March 13, 2023
Aglycosylated extracellular loop of inwardly rectifying potassium channel 4.1 (KCNJ10) provides a target for autoimmune neuroinflammationArnaud B Nicot, Jean Harb, Alexandra Garcia, et al.
Annals of Clinical and Translational Neurology|August 8, 2025
Durable B-Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple SclerosisAlexandra Garcia, Stephane Rodriguez, Emilie Dugast, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 22, 2023
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple SclerosisAlexandra Garcia, Emilie Dugast, Sita Shah, et al.
Brain : a Journal of Neurology|June 30, 2026
Blood cytotoxic natural killer-like CD8 + CD94+ T cells migrate to the brain and predict multiple sclerosis severityEmilie Dugast, Sita Shah, Isabel Vogel, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Journal of Autoimmunity|October 22, 2017
An intermediate level of CD161 expression defines a novel activated, inflammatory, and pathogenic subset of CD8<sup>+</sup> T cells involved in multiple sclerosisBryan Nicol, Marion Salou, Isabel Vogel, et al.
Brain Communications|March 13, 2023
Aglycosylated extracellular loop of inwardly rectifying potassium channel 4.1 (KCNJ10) provides a target for autoimmune neuroinflammationArnaud B Nicot, Jean Harb, Alexandra Garcia, et al.
Annals of Clinical and Translational Neurology|August 8, 2025
Durable B-Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple SclerosisAlexandra Garcia, Stephane Rodriguez, Emilie Dugast, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 22, 2023
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple SclerosisAlexandra Garcia, Emilie Dugast, Sita Shah, et al.
Brain : a Journal of Neurology|June 30, 2026
Blood cytotoxic natural killer-like CD8 + CD94+ T cells migrate to the brain and predict multiple sclerosis severityEmilie Dugast, Sita Shah, Isabel Vogel, et al.
Pageof 5